Zoltan Derdak
Medical Director Takeda Pharmaceuticals
Seminars
Tuesday 30th September 2025
4:15 pm Identifying MASH Patients with Active Fibrogenesis: Biomarker Strategies for Early Proof-of-Concept Antifibrotic Trials
- Differentiating fibrosis stage from fibrogenic activity in the context of antifibrotic therapy development
- Leveraging real-world screening data to characterize patients with active, ongoing fibrogenesis
- Exploring pre-identification tools (including but not limited to AST, FAST score and LiverPRO) and treatment monitoring strategies
